ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

LPTX Leap Therapeutics Inc

3.16
-0.05 (-1.56%)
Last Updated: 12:47:59
Delayed by 15 minutes

Period:

Draw Mode:

Volume 52,376
Bid Price 3.12
Ask Price 3.16
News -
Day High 3.33

Low
1.235

52 Week Range

High
10.20

Day Low 3.09
Company Name Stock Ticker Symbol Market Type
Leap Therapeutics Inc LPTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.05 -1.56% 3.16 12:47:59
Open Price Low Price High Price Close Price Prev Close
3.21 3.09 3.33 3.21
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
574 52,376 $ 3.21 $ 168,133 - 1.235 - 10.20
Last Trade Time Type Quantity Stock Price Currency
12:49:03 25 $ 3.15 USD

Leap Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
80.28M 25.57M - 0 -81.41M -3.18 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Leap Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LPTX Message Board. Create One! See More Posts on LPTX Message Board See More Message Board Posts

Historical LPTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.063.332.773.02185,5360.103.27%
1 Month2.444.392.413.09554,3630.7229.51%
3 Months2.724.392.1252.99326,9310.4416.18%
6 Months1.535.001.31112.95293,4861.63106.54%
1 Year3.54510.201.2354.38441,665-0.385-10.86%
3 Years17.6041.701.23519.551,153,920-14.44-82.05%
5 Years16.7041.701.23519.71920,611-13.54-81.08%

Leap Therapeutics Description

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205.

Your Recent History

Delayed Upgrade Clock